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ABSTRACT
Toll-like receptor 5 (TLR5) expression in the intesti-
nal epithelial cells (IECs) is critical to maintain health,
as underscored by multiple intestinal and extra-
intestinal diseases in mice genetically engineered for
IEC-specific TLR5 knockout. A gradient of expres-
sion exists in the colonic epithelial cells from the ce-
cum to the distal colon. Intriguingly, an identical gra-
dient for the dietary metabolite, butyrate also exists
in the luminal contents. However, both being critical
for intestinal homeostasis and immune response, no
studies examined the role of butyrate in the regula-
tion of TLR5 expression. We showed that butyrate
transcriptionally upregulates TLR5 in the IECs and
augments flagellin-induced immune responses. Both
basal and butyrate-induced transcription is regulated
by differential binding of Sp-family transcription fac-
tors to the GC-box sequences over the TLR5 pro-
moter. Butyrate activates two different protein ki-
nase C isoforms to dephosphorylate/acetylate Sp1
by serine/threonine phosphatases and phosphory-
late Sp3 by ERK-MAPK, respectively. This resulted
in Sp1 displacement from the promoter and binding
of Sp3 to it, leading to p300 recruitment and his-
tone acetylation, activating transcription. This is the
first study addressing the mechanisms of physiolog-
ical TLR5 expression in the intestine. Additionally, a
novel insight is gained into Sp1/Sp3-mediated gene
regulation that may apply to other genes.
INTRODUCTION
Toll-like receptors (TLRs) are a class of host pattern recog-
nition receptors, which recognize structurally conserved
molecules derived from the microbes and activate innate
immune responses (1). TLRs expressed by mucosal epithe-
lia are critical for the distinction between resident micro-
biota and the pathogens (2). While most TLRs are ex-
pressed at high levels by the immune cells, TLR5, which
recognizes flagellin fromGram-negative andGram-positive
bacteria is also expressed by various epithelial cells (3) and
serves pleiotropic functions through the activation of mul-
tiple intracellular signaling pathways (2). TLR5 expression
in the intestinal epithelium protects against microbial in-
fections and inflammation, tissue injury, radiation colitis,
pro-apoptotic stimuli and colon cancers (4). In addition,
it helps to maintain tolerance to commensals through the
generation of flagellin-specific immunoglobulin A, which
suppresses the flagellin gene expression in commensals (5).
Functional TLR5 expression is also required to maintain
gastrointestinal health, as suggested by the development
of intestinal dysbiosis, spontaneous colitis and obesity-
associated metabolic disorders in mice with intestinal ep-
ithelial cells (IECs)-specific TLR5 knockout (6). Flagellin
has been proposed as an adjunct therapy to colon cancers,
because it not only boosts the efficacy of radiation and
chemotherapy, but also protects the healthy tissues from the
adverse effects of such therapies (7). However, despite the
central role of TLR5 expression in gut physiology and im-
mune responses, the regulatory mechanisms for its expres-
sion in healthy and diseased intestine remain unknown.
Differential expression of TLRs in healthy and diseased
gut epithelia has been reported with vital consequences for
microbial pathogenesis, immune responses and homeosta-
sis. Aside from TLR expression altering with age, rapid
modulation of their expression occurs following the expo-
sure of cells to environmental stress, microbes and microbe-
derived factors and host mediators, such as cytokines (8).
TLR5 is downregulated in ulcerative colitis patients (9) and
in DSS colitis in mice, while the expression of TLR4 and
TLR2 is increased and other TLRs remain unchanged (10).
Pro-inflammatory cytokines, IFN- and GM-CSF upreg-
ulate TLR2 and TLR4 expression in monocytes, but sup-
*To whom correspondence should be addressed. Tel: +91 33 23537470 (Ext. 3203); Fax: +91 33 23632398; Email: dasss@icmr.org.in
C© The Author(s) 2016. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/), which
permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/44/12/5658/2457497 by O
kayam
a U
niversity user on 13 M
ay 2019
Nucleic Acids Research, 2016, Vol. 44, No. 12 5659
press TLR5 expression (11). A gradient of TLR expression
was reported along the length of the healthy gut with TLR5
maximally expressed in the proximal colon and gradually
decreasing toward the distal part. In contrast, TLR4 and
TLR2 are maximally expressed in middle and distal colon,
respectively, while their expression is lowest in the proximal
colon (10). However, the expression gradient is lost during
disease states, suggesting its critical importance in main-
taining gut physiology and overall health of the host organ-
ism.
Butyrate, a short chain fatty acid (SCFA), is naturally
produced in the gut by microbial fermentation of dietary fi-
bres. It is established as the most biologically active SCFA,
which plays an important role in themaintenance of normal
gut physiology and immune homeostasis by regulating cell
proliferation and differentiation, tight junction integrity,
apoptosis, anti-inflammatory and oxidative stress response,
membrane synthesis and sodium absorption (12,13). De-
pending on the dietary fibre contents, the physiological
concentration of butyrate varies between 1 and 20 mM
(14). The maximum concentration is found in the proxi-
mal colon, which gradually decreases distally (14). This is
similar to TLR5 and opposite to TLR4 expression in the
colonic epithelium (10). Earlier studies showed that bu-
tyrate induces differentiation of HT29 cells, leading to the
downregulation of TLR4 expression and suppression of
lipopolysaccharide-induced IL-8 expression (15). However,
it induces peptidoglycan-mediated chemokines production
in Caco-2 cells through the induction of Nod2 expression
(16). In addition, a recently published study has reported
that butyrate enhances flagellin-activated signals and ex-
pression of IL-8 and TNF- in human bronchial epithelial
cells (17). These findings led us to investigate whether bu-
tyrate regulates the physiological expression of TLR5 in the
intestinal epithelial cells.
We report here that butyrate enhanced flagellin-mediated
immune responses in the IECs through the induction of
TLR5 expression. It was regulated by differential bind-
ing of Sp1 and Sp3 to the TLR5 promoter. We report a
novel mechanism regulating Sp1/Sp3 swap at the TLR5
promoter, mediated through simultaneous modifications by
dephosphorylation/ acetylation of Sp1 via PKC-dependent
activation of serine/threonine (ser/thr) phosphatases and
phosphorylation of Sp3 by PKC--mediated ERK activa-
tion. These modifications led to enhanced p300 recruitment
and histone acetylation at the TLR5 promoter, giving an
insight into the specificity of histone acetylation process in
gene regulation. This study not only addressed the regula-
tion of physiological expression of TLR5 in the intestine,
but also revealed a novel mechanism of Sp1/Sp3-mediated
gene regulation.
MATERIALS AND METHODS
Reagents
Sodium butyrate was purchased from Sigma. Pharmaco-
logical inhibitors were from Sigma [Actinomycin-D, Cyclo-
heximide, Mithramycin A, H-7, Staurosporin, Rp-CAMP,
Sodium orthovanadate (vanadate), Bisindolylmaleimide-I,
Go6976, Rottlerin and Okadaic acid], Calbiochem (H-89,
U0126, SB203580, JNK-II and MG-132) and Promega
(LY294002). Antibodies were purchased from Abcam
(TLR5 and Sp1), Santacruz Biotechnology [Sp1 (sc-14027),
Sp3 (sc-644 and sc-13018), PKC- (sc-213), p300 (sc-584X),
p-Ser(4A3) (sc-81516), egr-1 (sc-189), c-myc (sc-789), TLR5
(sc-10742) and tubulin (sc-5286)], Cell Signaling (H3, H4,
p-PKC-, ERK, p-ERK, p-Thr, p-Tyr, Acetyl-Lys), Sigma
(HDAC1) andUpstate (Acetyl-H3 andAcetyl-H4). All oth-
ers chemicals were purchased from Sigma. Luciferase re-
porter constructs were bought from Promega. egr-1 over-
expression construct and TLR5 promoter deletion reporter
constructs were generated in laboratory. pN3-Sp3FL (Ad-
dgene plasmid # 24541) and pN3-Sp1FL (Addgene plasmid
# 24543) were gifts from Guntram Suske. Primers used for
the study are listed in Supplementary Table S1.
Cell culture
HT29, Caco-2, T-84, INT-407, SW480 and HEK293 cell
lines were purchased from American type culture collec-
tion (ATCC) and maintained as per the provider’s instruc-
tions. LoVo andCOLO205 cells were kindly provided byDr
P. Tsichlis, Tuft University. These cells were maintained in
DMEMorRPMI1640 supplemented with 10% fetal bovine
serum (FBS) and 100 U/ml Penicillin/Streptomycin (Invit-
rogen). Cells were cultured overnight in serum-free medium
before subjecting to the experiments.
Mice treatment with butyrate
Miceweremaintained according to theNationalGuidelines
for ethical animal treatment, approved byNational Institute
of Cholera and Enteric diseases (ICMR), Kolkata, India.
All the animal experiments were approved by Institutional
Animal Ethics Committee. BALB/c mice, 6–8 weeks old,
were fed with either phosphate buffered saline (PBS) (vehi-
cle) or butyrate (300 mol/kg body wt.) twice a day at 12
h intervals for 3 days. On day 4, mice were sacrificed and
colon were collected for Immunohistochemistry or for iso-
lation of colonic epithelial cells. Colonic epithelial cells were
isolated using low temperature method as described earlier
(18).
RNA isolation, reverse transcription PCR and real-time PCR
Total RNAwas extracted using TRIzol reagent (Invitrogen)
following the manufacturer’s protocol. One microgram of
DNA-free RNA was used for c-DNA synthesis using Su-
perscript II reverse transcriptase (Life technologies) follow-
ing the manufacturer’s protocol. qPCR was performed in
StepOnePlus (ABI) using SYBR green master mix (ABI)
with annealing/extension temperature at 60◦C for 1 min.
The specificity of PCR products was verified by melting
curve analysis. Relative quantitation was done by the com-
parative CT method (19). Data were presented after nor-
malization with GAPDH expression.
Immunohistochemistry
Three micrometers thick paraffin sections of colonic tissues
were deparaffinized and incubated in 3% hydrogen perox-
ide. After washing, sections were blocked with TBS con-
taining 10% goat serum and 1% BSA and stained overnight
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with 1:100 dilution of TLR5 antibody or isotype control an-
tibody. After incubation with HRP-conjugated goat anti-
mouse antibody (Pierce) for 30 min, the sections were de-
veloped with diaminobenzidine (DAB, Sigma) for 10 min
at room temperature. Sections were counterstained with
Hematoxylin for 1 min and mounted for microscopic anal-
ysis.
Flow cytometry
Cells were fixed in 4% paraformaldehyde and permeabilized
with PBS containing 0.1% Triton-X. Washed cells (106)
were stained with TLR5 antibody (2 g, Abcam) or IgG2a
isotype (BD biosciences) for 30 min at room temperature.
After washing, cells were stained with FITC-labeled anti-
mouse IgG antibody (1:200) (Jackson) for 20 min at room
temperature and analyzed by flow cytometry.
ELISA
Quantitation of IL-8 and CCL20 in the culture super-
natants of the experimental cells were measured using
ELISA kits (eBioscience) as per the manufacturer’s instruc-
tions.
Construction of reporter and expression plasmids
Various lengths of TLR5 putative promoter were amplified
by PCR using human genomic DNA as the template. PCR
products were cloned into pTZ57R/T vector (Fermentas)
and then subcloned into pGL3 basic vector (Promega). egr-
1 over-expression construct was generated by cloning the
PCR-amplified coding sequence into pCDNA3.1 (Invitro-
gen). All the recombinant clones were validated by sequenc-
ing.
Mutation, transfection and reporter assay
Mutations over the SP-A (M1) and SP-B (M2) sites were
introduced using the quick change site directed muta-
genesis kit (Stratagene); according to the manufacturer’s
protocol. Transient transfections were carried out using
Lipofectamine-LTX Plus (Invitrogen); according to the
manufacturer’s protocol. For reporter assays, cells were co-
transfected with the reporter construct and the internal
control (pRL-TK) vector. Cells were stimulated with bu-
tyrate 36 h after transfection and luciferase activity was
measured using the Dual Luciferase Reporter Assay system
(Promega); according to the manufacturer’s protocol. Rel-
ative reporter activity was plotted after normalization with
renila luciferase activity.
RNA interference and Gene knockdown
Validated siRNAs designed to knockdown the expression
of egr-1, c-myc, Sp1, Sp3, PKC- or MEK-1 and control
siRNA (Santacruz Biotechnology) were transfected into
HT29 cells with Lipofectamin-LTX plus reagent (Invitro-
gen); following the manufacturer’s protocol. Efficiency of
gene silencing was verified by immunoblotting 48 h post-
transfection.
Preparation of cytosolic and nuclear protein
Nuclear and cytoplasmic extracts from variously-treated
cells were prepared as described previously (19). Briefly,
HT29 cells were harvested by scraping, resuspended in low
salt buffer A [10 mM HEPES (pH 7.9), 1.5 mM MgCl2,
10 mM KCl] and incubated on ice for 15 min. After the
addition of Nonidet P-40 (0.5%, final concentration), the
cell suspensions were passed through a 21-gauge needle 5–
6 times. Cytoplasmic and nuclear fractions were separated
by centrifugation at 14 000 rpm for 10 min at 4◦C. Nuclear
proteins were extracted by incubating the cell pellet in high
salt buffer C [20 mM HEPES (pH 7.9), 420 mM NaCl, 1.5
mMMgCl2, 0.2 mMEDTA, 25% glycerol] for 30min on ice
with vigorous shaking (250 rpm) followed by centrifugation
at 14 000 rpm for 10 min at 4◦C. All the preparations were
made in presence of 1X protease inhibitor (Sigma) and 1X
phosphatase inhibitors cocktails (Calbiochem).
Immunoblot
Immunoblots were performed using the standard protocol
(19). In brief, post-experimental cells were lysed with Non-
idet P-40 lysis buffer [50 mM HEPES (pH 7.4), 100 mM
NaCl, 2 mM EDTA, 0.5% Nonidet P-40, 10% glycerol, 50
mM -glycerophosphate, 1 mM NaF, protease inhibitor
cocktail] and proteins in the samples were separated in SDS-
PAGE and transferred to a PVDF membrane (Millipore).
Blots were incubated overnight at 4◦C with primary anti-
bodies followed by HRP-conjugated secondary antibodies
for 1 h at room temperature. Blots were developedwith ECL
plus Western blot detection reagent (Pierce) and the chemi-
luminescence was transferred to autoradiographs. All the
Western blot experiments were repeated at least two times
and a representative blot is presented.
Immunoprecipitation (IP)
A total of 400 g of nuclear proteins from HT29 cells
were pre-clearedwith ProteinA/Gplus agarose beads (San-
tacruz) and the supernatants were incubated with 2 g rab-
bit Sp1 or Sp3 antibody or IgG overnight at 4◦Cwith gentle
rocking. Immune complexes were precipitated by incuba-
tion with 50 l of Protein A/Gplus beads for additional 1 h
followed by brief centrifugation. Beads were washed thrice
with NP-40 buffer, resuspended in 60 l of 2X sample load-
ing buffer and boiled for 5 min before SDS-PAGE and im-
munoblotting.
Electrophoretic mobility shift assay (EMSA)
DNA-binding activity was analyzed by electrophoretic mo-
bility shift assay (EMSA) as described (19). Briefly, nuclear
extracts of cells were incubated with 20 fmol of biotin-
labeled probes (3′-end biotin labeling was done according
to Pierce kit manual) in the binding buffer [10 mMTris (pH
7.5), 50 mM NaCl, 1 mMMgCl2, 0.5 mM DTT, 10% glyc-
erol, 0.1%NP-40, 0.5mMEDTA, 0.1g/l poly-dI.dC] for
30 min at room temperature. Supershift was performed by
adding respective antibodies 15 min prior to the addition of
biotin-labeled probe. Complexes were separated by gel elec-
trophoresis using a 6% non-denaturing polyacrylamide gel,
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transferred to a Nylon+ membrane and probed with HRP-
conjugated streptavidin for 15min. The substrate was added
to the membrane and autoradiogram was taken.
DNA affinity precipitation assay (DAPA)
DNA affinity precipitation assay (DAPA) was performed as
described earlier with modifications (20). Briefly, 200 g of
nuclear protein was incubated with 2 g of biotin-labeled
probe in 400 l of binding buffer [60 mM KCl, 12 mM
HEPES (pH 7.9), 4 mM Tris-HCl, 5% glycerol, 0.5 mM
EDTA, 1 mM DTT, 1X protease inhibitor mixture] on ice
for 45 min. DNA-protein complexes were pelleted down af-
ter incubation with 25 l of streptavidin microbeads (Mil-
tenyi Biotec) for 1 h at 4◦C. Proteins were eluted by boiling
in 2X sample loading buffer and analyzed by Western blot-
ting.
Chromatin immunoprecipitation (ChIP)
Quantitative chromatin immunoprecipitation (ChIP) as-
says were performed using EZChIPTM chromatin immuno-
precipitation kit (Upstate) following the manufacturer’s in-
structions. Briefly, treated and untreated HT29 cells were
crosslinked using formaldehyde and harvested by scrap-
ing. The cell pellet was resuspended in the lysis buffer pro-
vided with the kit, and sheared chromatin was immunopre-
cipitated overnight with 2 g of rabbit antibodies against
RNApolymerase II, Sp1, Sp3,Acetyl-H3,Acetyl-H4, p300,
HDAC1 or IgG (negative control), followed by incubation
with Protein G agarose for additional 1 h. The immunopre-
cipitated complex were sequentially washed with low salt,
high salt, LiCl andTris-EDTAbuffer followed by extraction
with elution buffer. The DNA-protein complexes were re-
versed and DNAwas purified by ethanol precipitation. The
relative binding of proteins to TLR5 promoter was quanti-
tatively analyzed by qPCR of precipitated DNA and input
DNA. Results are presented as percentages of the total in-
put DNA by using percent input method (% input = 100 ×
2 ∧ (Adjusted Ct of input − Ct of IP samples).
Statistical analysis
The data are presented as mean±SD of three independent
experiments. Statistical significance was calculated by Stu-
dent’s t-test using GraphPad Prism software (La Jolla, CA,
USA) and P < 0.05 was considered as significant.
RESULTS
Butyrate enhances flagellin-mediated immune responses in
the IECs
We investigated if butyrate enhanced immune responses
induced by flagellin in the IECs, as was reported for the
airway epithelial cells. Pre-treatment with butyrate signifi-
cantly stimulated the release of IL-8 and CCL20 in the cul-
ture supernatants of HT29 cells treated with rFliC (recom-
binant flagellin ofSalmonella typhimurium) (Figure 1A, left
and right). Mouse IL-8 homolog, KC and MIP-1 mR-
NAs were induced in the colonic epithelial cells isolated
from butyrate-treatedmice and stimulated ex vivowith rFlic
(Figure 1B, left and right). Flagellin-activated immune re-
sponses in the IECs are NF-B- and AP-1-dependent (21).
We investigated if butyrate enhanced activation of these
pathways by rFliC or activated different signaling mech-
anisms. Butyrate significantly upregulated rFliC-induced
NF-B and AP-1 consensus binding sequence-driven lu-
ciferase reporter activities in HT29 cells (Figure 1C, left and
right). To further investigate the role of butyrate in NF-
B and AP-1 activation, we analyzed the activation of sig-
naling pathways by Western blots. Butyrate and rFliC in-
dependently phosphorylated ERK and p38 MAPK, while
butyrate augmented rFliC-dependent phosphorylation of
MAPKs (Figure 1D). In contrast, NF-B activation as re-
vealed by IB (a negative regulator of NF-B) degra-
dation was induced by rFliC, but not by butyrate. In-
stead, butyrate enhanced IB levels in HT29 cells. How-
ever, increased NF-B activation was found when rFliC-
stimulated cells were pre-treated with butyrate. Taken to-
gether these results demonstrated that butyrate enhanced
flagellin-induced immune responses in the IECs by aug-
menting flagellin-activated signals.
Butyrate transcriptionally induces TLR5 expression that
does not require new protein synthesis in the IECs
Butyrate effects on flagellin-induced immune responses in
the IECs may be mediated through upregulated TLR5
expression or synergism between butyrate and TLR5-
activated signaling pathways. To investigate the modulation
of TLR5 expression, we stimulated HT29 cells with physi-
ological concentrations of butyrate for various durations.
Butyrate induced TLR5 mRNA expression in a dose- and
time-dependent manner with the highest levels of expres-
sion noted after treatment with 4 mM of butyrate for 24 h
(Figure 2A). This correlated with TLR5 protein expression
as studied byWestern blots and flow cytometry (Figure 2B).
Cell line specificity of the butyrate effects was excluded by
enhanced TLR5 expression in other IECs (Supplementary
Figure S1A). In vivo induction of TLR5 expression by bu-
tyrate was detected by Western blots of the colonic epithe-
lial cells or immunohistochemistry of the colonic tissues of
mice orally fed with butyrate (Figure 2C). Significantly en-
hanced DAB staining corresponding to TLR5 expression
was detected in the upper two-thirds of the colonic villi of
butyrate-treated mice. These results suggested that TLR5
upregulation by butyrate in the IECs might lead to acceler-
ated immune responses to flagellated intestinal pathogens.
To investigate the underlying mechanisms of butyrate-
induced TLR5 expression, we analyzed the changes in
TLR5 transcript levels after treatment of HT29 cells with
butyrate. The biological half life (t1/2) of TLR5 mRNA in
both unstimulated and butyrate-stimulated cells was 105
min (Supplementary Figure S1B), excluding any role for
increased mRNA stability in the enhanced TLR5 expres-
sion. In contrast, inhibition of transcription by actinomycin
D (ActD) completely abolished the butyrate effects (Fig-
ure 2D), indicating that TLR5 induction was transcription-
ally regulated. To further confirm transcriptional regula-
tion, RNA polymerase II recruitment to the TLR5 pro-
moter was examined by ChIP assays. Significant and pro-
gressive increase in RNApolymerase II binding to the prox-
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Figure 1. Butyrate enhances TLR5 ligand flagellin-mediated responses in IECs. (A) HT29 cells were pre-treated with 0 or 4 mM of butyrate for 24 h prior
to treatement with increasing concentration of rFliC for 18 h. IL-8 and CCL20 was measured by ELISA in the culture supernatants. (B) Colonic epithelial
cells isolated from mice fed with PBS- (Vehicle) or butyrate (300 mol/kg body wt.) twice a day at 12 h intervals for 3 days; were treated in vitro with
increasing concentration of rFliC for 3 h. qRT-PCR shows expression of KC and MIP-1 mRNA. (C) NF-B or AP-1 luciferase plasmids transfected
HT29 cells were pre-treated with butyrate as above, followed by increasing concentration of rFliC for 6 h and firefly luciferase activities were measured.
(D) HT29 cells were pre-treated with butyrate (4 mM) for 24 h, followed by rFliC (1 g/ml) for 60 min for p-ERK and p-p38 or 30 min for IB for
immunoblot. ERK, p38 and Tubulin were probed as loading control. *P < 0.05; **P < 0.01; ***P < 0.001 compared with butyrate-untreated samples.
imal TLR5 promoter was observed after butyrate treat-
ment (Figure 2E). Interestingly, pre-treatment with cyclo-
heximide (CHX), a global translation inhibitor, failed to
suppress butyrate-induced TLR5 mRNA expression (Fig-
ure 2F). This suggested that de novo protein synthesis was
not required for TLR5 transactivation by butyrate. To-
gether these results illustrated that butyrate transcription-
ally upregulated TLR5 expression in the IECs that was in-
dependent of de novo synthesis of transcriptional regulators.
Two GC-box sequences located at the positions -33/-22 and
-15/-2 of the TLR5 promoter is required for basal and
butyrate-induced transcriptional activities
To study the mechanism of TLR5 transactivation,
we analyzed the TLR5 putative promoter for tran-
scription factor binding sites using the software
TRANSFAC R©Professional (http://www.generegulation.
com/pub/programs/alibaba2/index.html) available at the
public domain. Consensus binding sequences for several
putative regulatory elements, including AP-1, Sp-family of
transcription factors (TFs), NF-B, egr-1 and c-myc were
identified within 820 bp upstream of the transcription start
site (TSS) (Figure 3A). To experimentally validate pro-
moter activities, luciferase reporter construct of the TLR5
putative promoter (−820 to +200 bp) was transfected into
HT29 cells. Basal reporter activities were ∼100-fold higher
compared with a promoterless reporter. Promoter activities
were further enhanced by 6- to 8-fold following butyrate
treatment (Figure 3B). To identify the promoter elements
responsible for basal and butyrate-induced TLR5 tran-
scription, luciferase constructs carrying serial deletions of
the TLR5 promoter from the 5′ end were transiently trans-
fected into HT29 cells. Reporter assays showed that the
minimal promoter containing the cis-regulatory elements
for basal as well as butyrate-inducible TLR5 transcription
was located within 38 bp upstream of the TSS (Figure 3B).
This contained two GC-box sequences (−33 to −22 bp and
−15 to −2 bp), designated as SP-A and SP-B, respectively,
which constituted the critical cis-regulatory elements for
the binding of Sp-family TFs. They were overlapped by
egr-1 and c-myc consensus binding sequences (Figure 3A).
To further confirm the role of the GC-boxes in TLR5
transcription, reporter constructs with mutated SP-A and
SP-B sites were transfected into the cells. Basal as well as
butyrate-induced reporter activities were reduced by ∼40%
and ∼60% for SP-A and SP-B sites, respectively. However,
it was completely abolished when both mutations were
present together (Figure 3C). These results indicated that
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Figure 2. Butyrate transcriptionally upregulates the TLR5 expression in IEC. (A) qRT-PCR showing TLR5 mRNA expression in HT29 cells treated with
physiological concentration of butyrate (1 to 20 mM) for 24 h (left) or with 4 mM of butyrate for indicated times (right). (B) Immunoblot of total lysates
from HT29 cells treated with butyrate (4 mM) for indicated times and probed with TLR5 and Tubulin (loading control) antibodies (upper); Histogram
showing increment of TLR5 expression in HT29 cells treated with butyrate as above and analyzed by flow cytometry (lower). (C) Immunoblot of TLR5
and Tubulin (loading control) in cell lysates of primary colonic epithelial cells isolated from mice fed with PBS (Vehicle) or butyrate (300 mol/kg body
wt.) twice a day at 12 h intervals for 3 days (left); immunohistochemistry showing TLR5 expression in colonic tissues frommice treated as above (right). (D)
qRT-PCR showing TLR5 mRNA expression in HT29 cells treated with actinomycin D (8 M) and butyrate, either alone or in combination. Actinomycin
D was added 1 h before butyrate. (E) ChIP assays showing IgG and RNA polymerase II binding to the TLR5 promoter in HT29 cells. (F) qRT-PCR
showing TLR5 mRNAs in HT29 cells treated with cycloheximide (CHX) (50 g/ml) for 1 h followed by butyrate. *P < 0.05; **P < 0.01 compared with
butyrate-untreated samples; ###P < 0.001 as compared with butyrate-treat samples.
the two GC-rich sequences above, predicted to bind the
Sp-family TFs played mandatory and synergistic roles in
the transcriptional regulation of TLR5 gene in the IECs.
Sp1 regulates the basal TLR5 transcription, while Sp3 medi-
ates induction by butyrate
To identify the trans-acting factors regulating TLR5 ex-
pression, we pre-treated HT29 cells with mithramycin, a
pharmacological inhibitor of Sp-family proteins. Increas-
ing doses of mithramycin progressively suppressed TLR5
expression under basal conditions as well as after stim-
ulation with butyrate (Figure 4A). Among the Sp-family
proteins, Sp1 and Sp3 are constitutively expressed and in-
volved in the gene regulation in various tissues through
binding to GC-rich regions (22). To investigate the role of
Sp1 and Sp3 in TLR5 transactivation, we silenced their ex-
pression by RNA interference and examined the effects on
TLR5 mRNA expression and promoter activities. Knock-
down of Sp1 and Sp3 protein expression was confirmed
by western blot analysis, which showed significantly re-
duced levels of Sp1 and all the isoforms of Sp3 proteins
in the respective siRNA-transfected cells (Figure 4B). In-
terestingly, Sp1 knockdown inhibited the basal promoter
activities and mRNA expression of TLR5 (Supplemen-
tary Figure S2A and Figure 4C), while knockdown of Sp3
suppressed butyrate-induced TLR5 promoter activities and
mRNA expression (Supplementary Figure S2B and Figure
4D). However, Sp3 exerted no role in basal TLR5 transcrip-
tion and Sp1 did not regulate the butyrate-induced effects.
In agreement with the above results, ectopic expression of
Sp1 and Sp3 dose-dependently enhanced the basal and in-
ducible promoter activities, respectively, driven by the SP-
A and SP-B sequences (Figure 4E and F). However, silenc-
ing or ectopic expression of egr-1 and c-myc did not regu-
late TLR5 expression in HT29 cells (Supplementary Figure
S2C, S2D). Taken together, these results demonstrated that
Sp1 was required to maintain the basal transcriptional ma-
chinery for TLR5 expression, while Sp3 was indispensable
for butyrate-induced transactivation.
Butyrate triggers decreased Sp1 and increased Sp3 binding to
the TLR5 promoter
To further explore the role of Sp-family TFs, we checked
their nuclear abundance in the untreated and butyrate-
treated HT29 cells. Sp1 and Sp3 were predominantly
present in the nuclear extracts of the cells and their rela-
tive abundance was unaltered by butyrate treatment (Figure
5A). To investigate the physical binding between the TLR5
promoter and the Sp-family proteins, we performed EMSA
assays with double-stranded biotinylated oligonucleotides
containing both SP-A and SP-B sequences and the nuclear
extracts of HT29 cells. DNA-protein complexes resolved in
a non-denaturing PAGE were represented by two distinct
bands, a prominent upper band in the un-stimulated cells
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Figure 3. Two GC-box near TSS of TLR5 promoter regulate both basal
and butyrate-induced promoter activities. (A) Sequence of the human
TLR5 gene putative promoter. The predicted transcription factor-binding
sites are underlined and labeled. SP-A and SP-B represent Sp1/Sp3 bind-
ing sites over the minimal promoter. Arrow indicates the TSS. M1 and
M2 denote mutated sequences over SP-A and SP-B, respectively. (B)
Firefly reporter assays with HT29 cells transfected with TLR5 promoter
deletion constructs. Lengths of the promoters used with predicted TFs
binding sites are indicated. **P < 0.01 as compared with pGL3 (empty
vector)-transfected samples (mock-reporter). (C) Firefly reporter assays
with TLR5 minimal promoter of mutated SP-A and/or SP-B site. *P <
0.05; **P < 0.01; ***P < 0.001 compared with the wild-type promoter;
#P < 0.05; ##P < 0.01; ###P < 0.001 as compared with butyrate-treated
wild-type promoter.
that had substantially diminished intensity after butyrate
treatment and a lower band, which was evident in butyrate-
treated cells and increased over time (Figure 5B). Supershift
assays using Sp1 and Sp3 antibodies confirmed that the up-
per band represented Sp1 complex, while DNA-bound Sp3
was responsible for the lower band shift. To further char-
acterize Sp1/Sp3 binding to the GC-box sequences over
the TLR5 promoter, we repeated the EMSA with oligonu-
cleotides containing either the SP-A or the SP-B. Binding
pattern of Sp1 and Sp3 was similar to that observed with
the probe containing the sequences together (Figure 5C).
Although weakly-bound complexes were apparent further
down the EMSA gel, they did not contain Sp1 and Sp3 as
suggested by the supershift assay. To investigate if differen-
tial Sp1/Sp3 binding to the TLR5 promoter is unique to
HT29 cells, we performed EMSA with the nuclear extracts
of the IEC line SW480 and a second epithelial cell line of
different origin (HEK293). The results for SW480 cells were
similar to HT29 cells (Supplementary Figure S3A); but for
HEK293 cells, no Sp3 binding to the TLR5 promoter was
observed (Supplementary Figure S3B). These results sug-
gest cell type specific regulation of TLR5 by the Sp-family
proteins. TLR5 promoter binding by Sp1 and Sp3 was fur-
ther studied by DNA affinity precipitation assay (DAPA)
coupled with immunoblots using biotin-labeled oligonu-
cleotides containing both SP-A and SP-B sites and the nu-
clear extracts of HT29 cells. We observed higher amounts
of DNA-bound Sp1 at the basal state, which decreased with
time after butyrate treatment. In contrast, butyrate induced
progressive increase of the long Sp3 isoform binding to the
DNA (Figure 5D). Finally, we investigated Sp-family pro-
tein binding to the endogenous TLR5 promoter byChIP as-
says. A time-dependent decrease of Sp1 and increase of Sp3
occupancy of the TLR5 promoter, but not of the GAPDH
promoter after butyrate treatment of the cells was noted
(Figure 5E and F). Similar assays with other gene promot-
ers regulated by Sp1 and/or Sp3 revealed that the basal pro-
moters of Sp1 and Sp3 are mostly occupied by Sp1, but not
Sp3 protein and the promoter occupancy by the above pro-
teins or RNApol II remained unaltered after butyrate treat-
ment (Supplementary Figure S3C). In contrast, p21 pro-
moter occupancy shows a similar pattern as the TLR5 pro-
moter, while significantly enhanced Sp3 binding was noted
for BAK promoter after butyrate treatment (Supplemen-
tary Figure S3D). The above data collectively suggested that
butyrate-induced TLR5 expression correlated with a switch
in the binding from Sp1 to Sp3 to the TLR5 promoter in
HT29 cells. However, this regulation is cell type specific and
may be different for other gene promoters.
Butyrate-induced TLR5 expression is regulated by ser/thr
phosphatases and PKC--mediated ERK activation
Published reports had shown a great diversity in the
transcriptional regulatory activities of Sp family tran-
scription factors, which could be determined at least in
part by the post-translational modifications, especially
phosphorylation/ dephosphorylation (23,24). To investi-
gate the mechanism behind TLR5 expression, we inhib-
ited different kinases and phosphatases using pharma-
cological inhibitors. Basal expression of TLR5 mRNA
was markedly suppressed by pan-Protein Kinase C in-
hibitors (H7, staurosporin), while butyrate-inducible ex-
pressionwas additionally blocked by the inhibitors ofMEK
(U0126). In addition, agents that inhibited both conven-
tional and novel isoforms of PKC [bisindolylmaleimide I
(BIM 1)] or PKC- (rottlerin) effectively countered butyrate
effects, while conventional PKC isoforms-specific inhibitor
(Go6976) failed to achieve this (SupplementaryFigure S4A,
Figure 6A). Moreover, butyrate-induced TLR5 expression
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Figure 4. Sp1 and Sp3 regulate basal and butyrate-induced TLR5 expression, respectively. (A) HT29 cells were pre-treated with increased concentrations
of mithramycin for 1 h followed by butyrate; qRT-PCR shows TLR5 mRNA expression. *P < 0.05; **P < 0.01; ***P < 0.001 compared with untreated;
#P < 0.05; ##P < 0.01; ###P < 0.001 as compared with butyrate treatment alone. (B) HT29 cells were transfected with control siRNA, Sp1 or Sp3-
specific siRNA. After 48 h, Sp1 and Sp3 proteins were detected by immunoblot analysis. (C and D) qRT-PCR showing (C) basal, or (D) butyrate (4 mM,
24 h)-induced expression of TLR5 mRNA in HT29 cells transfected with Sp1 and/or Sp3-specific siRNA. ***P < 0.001 compared with control siRNA
transfected; ###P < 0.001 as compared with control siRNA-transfected, butyrate-treated samples. (E and F) TLR5 promoter activities with HT29 cells
transfected with increasing concentrations of Sp1 and/or Sp3 expression plasmids and treated with or without butyrate (4 mM, 24 h). *P < 0.05; **P <
0.01; ***P< 0.001 compared with reporter transfection alone; #P< 0.05; ##P< 0.01; ###P< 0.001 compared with reporter-transfected, butyrate-treated
samples.
was dose-dependently suppressed by okadaic acid (oka.
acid) and high concentrations (≥100 M) of vanadate,
both of which inhibited ser/thr phosphatases (STPs) (lower
doses of vanadate was only effective in suppressing tyro-
sine phosphatases) (Figure 6B). Role of PKC- and MEK-
ERK signaling in butyrate-induced TLR5 expression was
further confirmed by silencing of the genes in HT29 cells
using RNA interference technology. The levels of respec-
tive proteins, as detected by western blots were markedly
reduced in the siRNA-transfected HT29 cells (Figure 6C,
inset), which showed significantly reduced expression of
TLR5 upon butyrate treatment (Figure 6C). Accordingly,
ectopic expression of PKC- dose-dependently enhanced
TLR5 promoter activity only when the cells were treated
with butyrate (Supplementary Figure S4B). The above find-
ings were further supported by butyrate-induced activa-
tion of the kinases and ser/thr phosphatases (STP) (Fig-
ure 6D and Supplementary Figure S4C). Interestingly, rott-
lerin suppressed ERKactivation, suggesting a role for PKC-
 (Figure 6E), while phosphatase activation was blocked by
okadaic acid and H7 (Figure 6F). The above finding con-
firmed the activation of ser/thr phosphatases in the pool
of butyrate-activated phosphatases and their regulation by
PKC signaling. Taken together, these results illustrated the
activation of ERK and STP by different PKC isoforms to
regulate TLR5 expression in butyrate-treated cells.
Butyrate promotes Sp1 and Sp3modifications through activa-
tion of ser/thr phosphatases and PKC-/ERK and regulates
their binding at TLR5 promoter
Our earlier results showed that TLR5 regulation was in-
dependent of de novo protein synthesis, and the expression
and nuclear translocation of Sp1 and Sp3 were unaltered by
butyrate treatment. To gain insights into the mechanisms
underlying butyrate-regulated differential binding of Sp1
and Sp3 to the TLR5 promoter, we investigated Sp1 and
Sp3 modifications by the kinases and phosphatases acti-
vated by butyrate. Serine phosphorylation of Sp1 was grad-
ually decreased after treatment with butyrate. This was ac-
companied by progressive serine phosphorylation of Sp3
along with acetylation of both Sp1 and Sp3. However, thre-
onine and tyrosine residue(s) of the above proteins were
not differentially phosphorylated (Figure 7A, left and right
panel). Althoughmultiple Sp3 isoforms are present inHT29
cells, phosphorylation was increased only for the longer iso-
form. In contrast, acetylation of both the isoforms was en-
hanced after butyrate treatment, albeit to a lesser extent
for the shorter isoform (Figure 7A, right panel and 7B).
Inhibitor treatment of the cells and gene-silencing exper-
iments showed that acetylation of the proteins was regu-
lated by STP, which also controlled Sp1 dephosphoryla-
tion. In contrast, phosphorylation of Sp3 was regulated
by PKC- and ERK (Figure 7B, Supplementary Figure
S5A). DAPA and ChIP assays showed that the inhibitors of
STP and pan-PKC, but not of PKC- and MEK1 reversed
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Figure 5. Butyrate differentially regulates Sp1 and Sp3 binding to TLR5 promoter. (A) Immunoblots showing Sp1 and Sp3 expression in the cytosolic
and nuclear extracts from the untreated- and butyrate-treated (4 mM, 24 h) HT29 cells. Histone H3 and Tubulin were probed as loading controls for the
nuclear and cytosolic extracts, respectively. (B and C) EMSA showing retarded bands due to binding of Sp1 and Sp3 present in the nuclear extracts of
HT29 cells to the biotin-labeled oligonucleotides containing the SP-A and/or SP-B sequences. Probes used contained both SP-A and SP-B sequences (B).
Mutated or 100-fold excess of the unlabeled oligo was used as the competitor. For supershift (ss), reaction was carried out in presence of antibodies (2
g) to Sp1, Sp3 or both. (D) DAPA. Biotin-labeled TLR5 minimal promoter was incubated with the nuclear extracts of untreated or butyrate-treated (4
mM for indicated times) HT29 cells. DNA-protein complexes were pulled down with streptavidin-coated beads, separated by Western blot and probed
with Sp1 and Sp3 antibodies. Total proteins in the nuclear extracts were immunoblotted as loading controls. (E and F) ChIP assays with IgG, Sp1 and
Sp3 antibodies in butyrate-treated (4 mM for indicated times) or untreated HT29 cells. qPCR showed IgG, Sp1 and Sp3 binding to endogenous (E) TLR5
promoter or (F) GAPDH promoter. *P < 0.05; **P < 0.01 compared with untreated.
butyrate-induced Sp1 de-recruitment from the TLR5 pro-
moter. Sp3 recruitment to the promoter after butyrate treat-
ment, on the other hand, was suppressed by all the kinase
and phosphatase inhibitors (Figure 7C and D). The above
results were further confirmed by ChIP assays in gene-
slienced HT29 cells (Supplementary Figure S5B). Consid-
ering that butyrate did not change the nuclear abundance
of the proteins, post-translational modifications through
phosphorylation/dephosphorylation regulated the binding
of Sp-family proteins to the TLR5 promoter. Interestingly,
basal Sp1 occupancy of the TLR5 promoter was decreased
after pan-PKC and ERK inhibition (Figure 7E), perhaps
due to their requirement for basal phosphorylation and pro-
moter recruitment of Sp1 to maintain the basal expression
of TLR5 in IECs. Together the above data suggest that bu-
tyrate dephosphorylated and acetylated Sp1 by STP, lead-
ing to its reduced binding to the TLR5 promoter. Simulta-
neously, phosphorylation of Sp3 by PKC-/ERK enhanced
its promoter recruitment. However, STP inhibition led to
impaired Sp1 dephosphorylation/ acetylation, resulting in
the failure of its replacement by phosphorylated Sp3 (Fig-
ure 7B–D).
Differential binding of Sp1/Sp3 leads to enhanced p300 re-
cruitment and histone acetylation at the TLR5 promoter and
dependent on STP- and PKC-/ERK-activation
Sp-group of TFs interact and cooperate with histone
deacetylases (HDACs) and histone acetyltransferases
(HATs) to form activator/repressor complexes by post-
translational modifications of the TFs/co-factors or to
induce epigenetic modifications of the gene promoter. We
investigated by DAPA followed by immunoblots and ChIP
assays for altered p300 and HDAC binding to the TLR5
promoter upon butyrate treatment. The results showed
enhanced recruitment of p300, but not HDAC1 to the
promoter, although nuclear abundance of the proteins was
unaltered after butyrate treatment. Moreover, no acety-
lated proteins were detected in the regulatory complexes
in the untreated and butyrate-treated cells (Figure 8A and
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Figure 6. Butyrate induced TLR5 expression depends on activation of PKC-/ERKand ser/thr phosphatases. (A andB) qRT-PCR showing TLR5mRNA
expression in HT29 cells, treated with bisindolylmaleimide I (BIM 1, 5 M), Go6976 (20 M) or Rottlerin (10 M) for 1 h followed by butyrate (4 mM)
for 24 h (A), or increasing concentrations of vanadate (10, 25, 50 and 100 M) or okadaic acid (10, 25, 50 and 100 nM) for 1 h before treatment with
butyrate (B). (C) qRT-PCR showing basal or butyrate (4 mM, 24 h)-induced expression of TLR5 mRNA in HT29 cells transfected with control siRNA,
PKC- or MEK-1 siRNA. Immunoblots showing knockdown of PKC- and MEK-1 (Inset). ##P < 0.01 as compared with control siRNA transfected
but butyrate treated. (D) Immunoblots of untreated and butyrate-treated (4 mM for indicated times) HT29 cell lysates probed with p-PKC- and p-ERK.
Total PKC- and ERK were probed as loading control. (E) Immunoblots showing p-ERK and ERK (loading control) in lysates of untreated or butyrate
(4 mM, 6 h)-treated HT29 cells pretreated with Rottlerin (10 M), U0126 (10 M) or okadaic acid (100 nM). (F) Specific phosphatase activities (U/mg
of protein) measured by calorimetric assay using pNPP as a substrate, in HT29 cells pretreated with vanadate (100 M), okadaic acid (100 nM), H7 (10
M), Rottlerin (10 M) and U0126 (10 M) for 1 h, followed by butyrate (4 mM, 6 h). **P < 0.01 as compared with untreated; #P < 0.05; ##P < 0.01;
###P < 0.001 compared with butyrate treatment alone.
B). Furthermore, pre-treatment of the cells with C646,
a specific p300/CBP inhibitor significantly suppressed
butyrate-induced TLR5 expression (Figure 8C), illustrat-
ing its role in TLR5 transactivation. Next, we investigated
if p300 recruitment to the promoter resulted in epigenetic
modifications due to histone acetylation. Butyrate signifi-
cantly induced histone H3 andH4 acetylation in HT29 cells
(Supplementary Figure S6A). ChIP assays showed that
butyrate promoted accumulation of acetylated H3 and H4
at the binding site of Sp1/Sp3 regulatory complexes over
the TLR5 promoter (Figure 8D). Since butyrate may exert
the above effects through direct HDACi activities without
removing HDAC from the promoter, we addressed this
issue by pre-treating the cells with STP and PKC-/ERK
inhibitors. ChIP assays showed that the occupancy of
acetyl-H3, acetyl-H4 and p300 to the TLR5 promoter was
significantly decreased in the inhibitor-treated cells (Figure
8E). This suggested that histone acetylation at TLR5
promoter was the consequence of enhanced p300 recruit-
ment rather than the direct HDAC inhibitory activities
of butyrate. Similar results were found for p21 promoter
except that histone acetylation was regulated by STP,
but not PKC-/ERK, indicating additional acetylation
mechanisms. In contrast, histone was not acetylated for
BAK promoter despite enhanced recruitment of p300 by
butyrate treatment (Supplementary Figure S6B–D). Taken
together the above results suggested that butyrate-induced
switch between Sp1 and Sp3 in the regulatory complexes
was accompanied by p300 recruitment to the TLR5 pro-
moter, leading to TLR5 transactivation through histone
acetylation.
DISCUSSION
TLR5 expression in the gut epithelium is critical for nor-
mal gut physiology and immune responses, and the loss of
expression has been associated with altered gut microbiota
composition, inflammatory bowel diseases, metabolic syn-
dromes and carcinogenesis (4,6,9). However, the expression
is restricted to the villi (25), the most differentiated part of
the intestinal epithelium and a downward gradient exists
from the proximal to the distal colon (10). This underscores
the importance of stringent regulation of TLR5 expression
in the gut epithelium. However, no study has so far been
undertaken to unearth the mechanisms behind the phys-
iological regulation of TLR5 expression. We report here
that short chain fatty acid butyrate, one of the most bio-
logically active dietary metabolites in the colon, transcrip-
tionally upregulates TLR5 expression in the IECs and en-
hances flagellin-mediated immune responses. We identified
two GC-box sequences within 38 bp upstream of the TSS,
which differentially bind Sp1/Sp3 to regulate both basal
and butyrate-induced TLR5 promoter activities. While Sp1
regulates the basal expression of TLR5, Sp3 mediates the
butyrate role. Promoter binding of Sp1 was high at the
basal state, but diminished after butyrate treatment due
to dephosphorylation by ser/thr phosphatases. In contrast,
ERK-dependent Sp3 phosphorylation induced by butyrate
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Figure 7. Butyrate regulates Sp1 and Sp3 modification and binding de-
pendent on STP and PKC-/ERK. (A) Nuclear extracts isolated from un-
treated and butyrate (4 mM for indicated times)-treated HT29 cells were
immunoprecipitated with Sp1 (left), Sp3 (right) or IgG antibody, followed
by immunoblotting for phosphorylation and acetylation. Sp1 and Sp3 to-
tal proteins were probed as loading controls. (B) Untreated and butyrate
(4 mM, 24 h)-treated HT29 cells were pre-treated with or without okadaic
acid (100 nM), Rottlerin (10 M) or U0126 (10 M). Nuclear extracts
from the cells were immunoprecipitated with Sp1, Sp3 or IgG antibody,
resolved in SDS-PAGE and immunoblotted as above. (C) DAPA. Biotin-
labeledTLR5minimal promoterwas incubatedwith the nuclear extracts of
untreated or butyrate (4 mM, 24 h)-treated HT29 cells, pre-treated with in-
hibitors. DNA-protein complexes were pulled down as above and probed
with Sp1 and Sp3 antibodies. Total proteins in the nuclear extracts were
immunoblotted as loading controls. (D and E) ChIP asays. DNA-protein
complexes from (D) butyrate-treated or (E) untreated HT29 cells, pre-
treated with H7 (10 M), okadaic acid (100 nM), Rottlerin (10 M) or
U0126 (10 M) were immunoprecipitated with IgG, Sp1 or Sp3 antibody.
DNA corresponding to TLR5 minimal promoter was amplified by qPCR.
*P < 0.05, **P < 0.01, ***P < 0.001 as compared with untreated; #P <
0.05, ##P< 0.01 as comparedwith butyrate-treated but inhibitor untreated
samples.
augmented its binding affinity for the same regulatory re-
gions as Sp1. Two different PKC isoforms were involved in
Sp1 and Sp3 modifications and also regulated the recruit-
ment of p300 and acetylayed histones H3 and H4 to the
TLR5 promoter, leading to transcriptional activation.
Butyrate induces global changes in gene expression. In
the intestine, it is involved in the maintenance of gut physi-
ology andmounting of immune responses (26,27). Recently,
flagellin-mediated IL-8 and TNF- expression in the hu-
man bronchial epithelial cells was shown to be enhanced
with the treatment of phenylbutyrate (a synthetic derivative
of butyrate) (17), although the mechanisms were not stud-
ied. We found similar effects with natural butyrate treat-
ment of the IEC line HT29. Butyrate upregulated TLR5 ex-
pression and enhanced the flagellin-induced signaling and
downstream responses. Functional expression of TLR5 in
vivo was also modulated by butyrate. Consistent with the
previous reports (25), staining of TLR5 was primarily con-
fined to the vertically more differentiated villus surface
rather than the crypt. It is believed that differentiation and
migration of intestinal cells in the gut is regulated by bu-
tyrate. In addition, maximum TLR5 expression was found
in the cecum (10), where butyrate concentration was also
reported to be the highest (14). These findings anticipated
butyrate as a candidate involved in the differential regula-
tion of the TLR5 expression in the gut lumen.
Species-specific regulation of TLR expression has been
reported earlier. Murine TLR2 expression is upregulated
by LPS, mycobacterial products and NF-B activation,
whereas TLR2 expression in humans is unaffected by
them (28). Moreover, LPS upregulates TLR3 expression in
murine macrophages through the induction of autocrine
INF-, but blocks INF--induced TLR3 expression in the
human myloid dendritic cells (29). However, our study
showed similar levels of TLR5 expression in the untreated
and butyrate-treated human and murine IECs. TLR5 pro-
moter sequences in the above species showed 53.9% homol-
ogy with conserved regulatory regions (data not shown),
suggesting similar regulatory mechanisms behind TLR5 ex-
pression across the species.
Transcriptional regulation by butyrate through GC-rich
sequences over the gene promoters was reported for sev-
eral genes (30–35). These sequences are frequently bound
by ubiquitously-expressed Sp-family TFs, leading to aug-
mented or attenuated gene expression in a spatio-temporal
manner. Two Sp-family proteins, namely Sp1 and Sp3work-
ing independently or in collaborations, were shown to reg-
ulate both constitutive and inducible expression of a large
number of genes (23,24). In our study, Sp1 controlled the
basal transcriptional machinery of TLR5, while stimula-
tion with butyrate dislodged Sp1 from the promoter and
recruited Sp3. Similar observations of differential bind-
ing of Sp1/Sp3 were earlier reported for BAK, p21, ma-
jor vault protein (MVP) and Na+/H+ exchanger (NHE)3
(32,34–36). However, Sp1/Sp3 modifications required for
the switch in promoter binding were not well-described. We
identified the post-translational modifications that allowed
Sp3 binding over Sp1 to the GC-boxes of the TLR5 pro-
moter and transcriptional activation. This demonstrated a
novel mechanism of gene regulation by the Sp-family pro-
teins.
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Figure 8. Enhanced p300 recruitment and histone acetylation at TLR5 promoter by butyrate was dependent on STP and PKC-/ERK: (A) DAPA. Biotin-
labeled TLR5minimal promoter was incubated with the nuclear extracts of untreated or butyrate (4mM, 24 h)-treatedHT29 cells. DNA-protein complexes
were pulled down as above and probed with p300, HDAC1, Sp1, Sp3 or acetyl-Lys antibody. Total proteins in the nuclear extracts were immunoblotted as
loading controls. (B) ChIP analysis with antibodies p300, HDAC1 or IgG in untreated or butyrate (4 mM, 24 h)-treated HT29 cells. DNA corresponding to
TLR5minimal promoter was amplified by qPCR. (C) qRT-PCR showing TLR5mRNAexpression inHT29 cells pre-treatedwith increasing concentrations
of p300 inhibitor (10, 25 and 50 M) for 1 h followed by butyrate (4 mM, 24 h). (D) ChIP analysis with antibodies against acetylated H3, H4 or IgG in
untreated or butyrate (4 mM, 24 h)-treated HT29 cells. DNA corresponding to TLR5 minimal promoter was amplified by qPCR. (E) ChIP analysis with
antibodies p300, acetyl-H3, acetyl-H4 or IgG in untreated or butyrate (4 mM, 24 h)-treated HT29 cells, pre-treated with different inhibitors (as indicated).
DNA corresponding to TLR5 minimal promoter was amplified by qPCR. *P < 0.05; **P < 0.01 as compared with untreated; #P < 0.05; ##P < 0.01;
###P < 0.001 as compared with butyrate-treated alone.
Posttranslational modifications of Sp1 and Sp3 may reg-
ulate their stability, promoter-binding affinity and trans-
activation potential (23,24). Lysine acetylation and serine
dephosphorylation of Sp1 by butyrate in our study might
be responsible for reduced binding to the TLR5 promoter.
Sp1 acetylation may increase or decrease the DNA bind-
ing affinity, depending on the stimuli and the cell lines
tested (24). An acetylated residue (lysine703) in the DNA-
binding domain of Sp1 was associated with reduced bind-
ing to the promoter and transcriptional downregulation of
Neuropilin-1 (NRP-1), a transmembrane receptor for vas-
cular endothelial growth factor (VEGF) (37). In contrast,
increased binding of acetylated Sp1 to the tumor suppressor
gene PTEN promoter in Hela cells also repressed transcrip-
tion by recruiting more HDAC1, which resulted in the de-
velopment and/or aggressiveness of cancers (38). However,
no acetyl-Sp1 was detected in the promoter-bound com-
plexes of P21, BAK (32) and TLR5 after butyrate treat-
ment, despite substantial increase in transactivation and
the pool of acetylated Sp1 in the nucleus. This suggests
that acetylation of Sp1 either suppressed its binding affinity
and/or played a minor role in transcriptional activation.
Phosphomodifications of Sp1 protein regulate DNA-
binding and transcriptional activity (23,24). We observed
more serine phosphorylation of Sp1 and stronger binding
to the TLR5 promoter in untreated compared to butyrate-
treated HT29 cells. Serine phosphorylation of Sp1 may
be regulated by the constitutive cellular signaling path-
ways regulating the cell growth and cell division. Butyrate-
induced dephosphorylation of Sp1 by STP in HT29 cells,
leading to reduced binding to the TLR5 promoter was in-
hibited by okadaic acid, a potent inhibitor of PP1 and
PP2A. PP1 was shown to suppress the binding affinity
of Sp1 and inhibit the promoter functions of ENaC2
and mouse vesicular glutamate transporter 2 (mVGLUT2)
gene in the lung epithelial cells and mouse pancreatic -
cell line, respectively (39,40). Dephosphorylation by other
phosphatases, such as protein tyrosine phosphatases and al-
kaline phosphatase were reported to inhibit recruitment to
VEGF and AKR1C1 promoters, respectively, and suppress
gene expression (41,42). Since okadaic acid also suppressed
Sp1 acetylation, we cannot completely exclude if acety-
lation contributed to butyrate-mediated de-recruitment of
Sp1 from the TLR5 promoter.
Sp3-mediated transcriptional regulation appears to be
more complex due to the presence of different isoforms and
their post-translational modifications (43). Regulation of
gene expression by Sp3 isoforms appears to be gene and
promoter specific, as suggested by butyrate-mediated reg-
ulation of NHE3 and NHE8 expression in Caco-2 cells.
While two Sp3-containing complexes were formed atNHE3
promoter, only one Sp3 complex atNHE8 promoter was de-
tected in the same cell line (35,44). We found expression of
multiple Sp3 isoforms in HT29 cells, but butyrate induced
phosphorylation/acetylation predominantly of the long
isoform. Variations in the expression and post-translational
modifications of the isoforms may explain, in part, differ-
ential gene regulation by Sp3. Two long isoforms may be
transcriptional activators or repressors, whereas small iso-
forms always function as repressors. All isoforms of Sp3
may be SUMO-modified at lysine551, which represses tran-
scription (43). We found that the relative amounts of dif-
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ferent isoforms before and after butyrate treatment in the
cytosolic and nuclear extracts remained the same. Waby
et al. (2010) concluded that decreased binding of acetylated
Sp1 to p21 promoter perhaps allowed access to Sp3, lead-
ing to transcriptional upregulation (32). However, knock-
down of Sp1 inhibited the basal transcription of TLR5
in HT29 cells. Overexpression of Sp3 didn’t influence the
basal TLR5 expression, but transactivation was markedly
enhanced when the cells were treated with butyrate. Given
that nuclear abundance of Sp3 remained unaltered after bu-
tyrate treatment, these results suggested that Sp3 required
post-translational modifications for DNA binding. Kiela,
PR et al. (2007) showed that acetylation of Sp3 and phos-
phorylation of Sp1 with butyrate might result in enhanced
promoter binding of Sp3 and transactivation of NHE3 in
Caco-2 cells (35). In contrast, butyrate-mediated Sp3 acety-
lation suppressed human insulin-like growth factor-binding
protein-3 expression in Caco-2 cells (45). We observed en-
hanced acetylated Sp3 levels in HT29 cells, but not in the
TLR5 transactivation complex. Recently, the role of phos-
phorylation of the longer Sp3 isoform in binding to the
promoter and transcriptional activation has been reported
(24,46). We found enhanced pool of phosphorylated long
isoform of Sp3 in the nuclei of butyrate-treated cells. The
kinetics of Sp3 phosphorylation correlated with its recruit-
ment to the TLR5 promoter, suggesting that phosphoryla-
tion may potentially underlie enhanced promoter-binding
of Sp3. However, Sp1 dephosphorylation continues to be a
pre-requisite for its replacement by Sp3 from the promoter,
necessitating further investigations into the atomic interac-
tions of Sp-family proteins with the TLR5 promoter and
their binding affinity before and after butyrate treatment.
An array of protein kinases (PKA, PKC, MAPK, Ca-
sein kinase and Calmodulin kinase) and phosphatases
(ser/thr and tyrosine phosphatases) were reported to post-
translationally modify Sp1 (23,24). Although PKC phos-
phorylates a large number of target proteins, its role in de-
phosphorylation via activation of phosphatases was also re-
ported. Activation of PKC by 4-phorbol 12-myristate 13-
acetate (PMA) enhanced the activity of PP1, a ser/thr phos-
phatase, in human breast cancer cell line, which dephospho-
rylated p38 MAPK (47). PKC--activated PP2A reduced
the tyrosine hydroxylase activity and dopamine synthesis in
PC12 cells (48). In the current study, STPs were activated
downstream of PKC in the butyrate-treated cells and reg-
ulated not only dephosphorylation, but also acetylation of
Sp1.While PKC-was not involved, the particular PKC iso-
form(s) responsible for the above modifications were not
identified. In contrast, butyrate-induced phosphorylation
of Sp3 and binding to the TLR5 promoter were dependent
on PKC- induced ERK activation. Limited information
exist about Sp3 regulation by different stimuli, although in-
volvement of ERK was reported earlier (46,49). One ERK
phosphorylation site in the long isoform of Sp3 (serine73)
was predicted as critical for VEGF expression (49). How-
ever, Sp3 phosphorylation by PKC--dependent ERK acti-
vation is a novel signaling mechanism.
Butyrate modulates the activation of multiple cellular
signaling pathways to induce global changes in gene ex-
pression. Butyrate activates G-protein coupled receptor
(GPCR), GPR43 to regulate the size and function of
colonic Treg cell pool in mice and protect from colitis (50).
SCFAs including butyrate activate GPR41 and GPR43 in
the IECs and mediate protective immunity and tissue in-
flammation in mice through the activation of ERK1/2 and
p38 MAPK signaling pathways (51). We had earlier re-
ported that butyrate induced cathelicidin expression in the
intestinal epithelial cells, which was regulated by cAMP-
dependent CREB and AP-1 activation (19). While this
may be regulated by GPCR activation, GPCR-independent
cAMP-PKA-CREB signaling pathway activation by bu-
tyrate in Caco-2 cells was also reported (52). Butyrate may
augment PKC and MAPKs activity, such as during ery-
throid proliferation and differentiation (53). Blockade of
PKC- and p38 MAPK in colorectal adenoma cells abro-
gated pro-apoptotic effect of butyrate, while Inhibition of
ERK diminished Gi2 and choline acetyltransferase gene
activation in K562 and CHP126 cells, respectively (54,55).
Moreover, butyrate-activated PKC- was also shown to be
critical for Epstein–Barr virus (EBV) reactivation or induc-
tion of EBV lytic cycle in nasopharyngeal carcinoma (NPC)
cell line (56). However, two different isoforms of PKC, reg-
ulating differential modification and DNA binding of Sp1
and Sp3 through simultaneous activation of ser/thr phos-
phatases and kinases is a novel underlying mechanism of
butyrate action.
The interaction of TATA-binding protein and associated
factors (both activators and/or repressors) with the regula-
tory transcriptional complexes was proposed as crucial de-
terminant of the specificity of gene regulation (57). Post-
translational modifications of TFs enhance their interac-
tion with the regulatory proteins. We observed increased
p300 recruitment and histone acetylation of the TLR5min-
imal promoter with butyrate treatment. Being a well known
HDAC inhibitor, butyrate directly binds toHDACs, leading
to enhanced activity of the existing HATs in the complex
and increased transcription through histone or non-histone
protein acetylation (57). In contrast, enhanced recruitment
of p300 and histone acetylation on the TLR5 promoter fol-
lowing butyrate treatment was dependent on the differen-
tial regulation of Sp1/Sp3, since STP and PKC-/ERK in-
hibitors reversed the butyrate effects. Suppression of p300
recruitment and histone acetylation with PKC-/ERK in-
hibition suggested that increased amounts of p300 in the
TLR5 transactivation complex is likely to be associated
with the recruitment of phosphorylated Sp3. This is simi-
lar to the regulation of ChM-I gene through the associa-
tion of YY1 and p300 with Sp1/Sp3. YY1 negatively reg-
ulated the expression of ChM-I through deacetylation by
Sp1-dependent recruitment of histone deacetylase, whereas
transcriptional co-activator p300 binds to core promoter
with Sp3 but not Sp1 and activate ChM-I through histone
acetylation (58). The differential binding of Sp1/Sp3 and
recruitment of p300 was also observed at BAKand p21 pro-
moter.However, histonewas not acetylated at the BAKpro-
moter, and p300 recruitment, but not histone acetylation at
p21 promoter was regulated by PKC-/ERK. Earlier stud-
ies suggested involvement of otherHATs likeGCN5 for p21
regulation (59,60). Progressive accumulation of p300 at the
TLR5 transactivation complex through differential regula-
tion of Sp1/Sp3 provides an example of selectivity in the
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gene regulation by histone modifications with a global reg-
ulator like butyrate.
This study presents a novel insight into the transcrip-
tional regulation by Sp1/Sp3 swap that is mediated through
differential regulation of Sp1 and Sp3 by PKC signaling
pathways. This is the first study that addressed physiologi-
cal regulation of TLR5 gene expression in the intestinal ep-
ithelium, enabling us to further understand the molecular
mechanisms of the maintenance of normal gut physiology
and homeostasis, which may potentially lead to the devel-
opment of new therapeutics targeted to TLR5 for the ame-
lioration of intestinal diseases and restoration of normalcy.
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